Effectiveness and Safety of Fixed‐Dose Combination Metformin and Empagliflozin in Type 2 Diabetes: A Prospective, Multicenter, Real‐World Study From China

BACKGROUND: This study assessed the real-world effectiveness and safety of a fixed-dose combination (FDC) of metformin and empagliflozin in Chinese patients with type 2 diabetes mellitus (T2DM). METHODS: This prospective, multicenter, real-world study enrolled consecutive patients with T2DM treated with the FDC of metformin and empagliflozin between August 2023 and August 2025 across 50 clinical centers in China. The primary endpoint was the 6-month glycemic clinical control rate (HbA1c < 7.0%). The safety outcome included adverse events (AEs), major adverse cardiovascular events (MACEs), and major adverse kidney events (MAKEs). RESULTS: , median HbA1c was 8.3%, and median diabetes duration was 3 years; 34% of patients were female. At 6 months, the proportion of patients achieving HbA1c < 7.0% increased from 20.2% to 58.9%, with median HbA1c falling by about 1.1%-1.2%. Treatment also lowered fasting plasma glucose, body weight, and waist and hip circumference, and modestly reduced blood pressure, improving blood pressure control and shifting the BMI distribution toward normal weight. Subgroup analyses showed higher HbA1c target attainment in younger patients, those with lower baseline HbA1c, and those with higher BMI. Most patients remained on metformin/empagliflozin. AEs, MACEs, MAKEs, ketoacidosis, and genitourinary infections were infrequent. CONCLUSION: In this large-scale, real-world study in a Chinese population, the empagliflozin and metformin FDC improved long-term HbA1c control and was well tolerated.

Authors

Institutions

Publication Details

Journal
Journal of Diabetes
Published
2026-09-28
DOI
https://doi.org/10.1111/1753-0407.70273
Primary Topic
Diabetes Treatment and Management
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
article

Effectiveness and Safety of Fixed‐Dose Combination Metformin and Empagliflozin in Type 2 Diabetes: A Prospective, Multicenter, Real‐World Study From China

Xiaojia Lou, Guangju Zhou, Xiaosu Bai, Weijian Ke et al.
Journal of Diabetes
Diabetes Treatment and Management
article

Effectiveness and Safety of Fixed‐Dose Combination Metformin and Empagliflozin in Type 2 Diabetes: A Prospective, Multicenter, Real‐World Study From China

Xiaojia Lou, Guangju Zhou, Xiaosu Bai, Weijian Ke, Xuehua Jiao, Li Hong, Liwu Xu, Yuwen Shi, Shao Zhong, 崔丽娟, Hua Qian, Ying Pan, Xuefeng Li, Weikun Gong, Yanbing Li, Lingling Xu, Xin Yan, Yuan Liang, Fenjuan Xu, Xuan Lin, Fu Songbo, Liyun Wang, Juan Yuan, Wei Lu, Junhua Song, Lijun Wang, Fenghua Lan, Bo Yan, Wukun Ma, Hongbin Zhu, Yuxiao Bai, Huike He, Lingxiao Wang, Hui Chen, Yanhua Jiang, Guangwu Zhang, Xiaosi Li, Yinghong Kong, Yanqiu Wang, Yufan Wang, Juan Zheng, Fang Wang, Bin Wang, Fen Li, Ping Shi, Fuxing Sha, Liying He, Hongyu Duan, Xiaoli Chen, Wei Shao, Xin Mou, Zhenhua Wang
article en

Abstract

BACKGROUND: This study assessed the real-world effectiveness and safety of a fixed-dose combination (FDC) of metformin and empagliflozin in Chinese patients with type 2 diabetes mellitus (T2DM). METHODS: This prospective, multicenter, real-world study enrolled consecutive patients with T2DM treated with the FDC of metformin and empagliflozin between August 2023 and August 2025 across 50 clinical centers in China. The primary endpoint was the 6-month glycemic clinical control rate (HbA1c < 7.0%). The safety outcome included adverse events (AEs), major adverse cardiovascular events (MACEs), and major adverse kidney events (MAKEs). RESULTS: , median HbA1c was 8.3%, and median diabetes duration was 3 years; 34% of patients were female. At 6 months, the proportion of patients achieving HbA1c < 7.0% increased from 20.2% to 58.9%, with median HbA1c falling by about 1.1%-1.2%. Treatment also lowered fasting plasma glucose, body weight, and waist and hip circumference, and modestly reduced blood pressure, improving blood pressure control and shifting the BMI distribution toward normal weight. Subgroup analyses showed higher HbA1c target attainment in younger patients, those with lower baseline HbA1c, and those with higher BMI. Most patients remained on metformin/empagliflozin. AEs, MACEs, MAKEs, ketoacidosis, and genitourinary infections were infrequent. CONCLUSION: In this large-scale, real-world study in a Chinese population, the empagliflozin and metformin FDC improved long-term HbA1c control and was well tolerated.

Journal of DiabetesVol. 18(10)
Ningbo University (CN), Hebei Medical University (CN), Jiangsu University (CN), Sun Yat-sen University (CN), Guangxi Medical University (CN), Henan University of Science and Technology (CN), Xuzhou Medical College (CN), Shanghai Jiao Tong University (CN), Anhui University of Science and Technology (CN), Nantong University (CN), Wenzhou Medical University (CN), Soochow University (CN), Xian Central Hospital (CN), The Fourth People's Hospital of Zibo City (CN), Taizhou Second People's Hospital (CN), Huaian First People’s Hospital (CN), Kaifeng University (CN), ShenZhen People’s Hospital (CN), Zhangjiagang First People's Hospital (CN), Affiliated Hospital of North Sichuan Medical College (CN), First People's Hospital of Kunshan (CN), Fourth Hospital of Changsha (CN), Ningbo Medical Center Lihuili Hospital (CN), Shaoxing Second Hospital (CN), Xingtai People's Hospital (CN), Jiangxi Pingxiang People's Hospital (CN), The First People's Hospital of Changde (CN), Lanzhou University Second Hospital (CN), The First Affiliated Hospital, Sun Yat-sen University (CN), Shanghai First People's Hospital (CN), Huainan Normal University (CN), Kaifeng City Children's Hospital (CN), Affiliated Hospital of Shaanxi University of Chinese Medicine (CN), First Hospital of Jiaxing (CN), Yixing People's Hospital (CN), The Second Affiliated Hospital of Bengbu Medical College (CN), Southern Medical University Shenzhen Hospital (CN), The First People's Hospital of Guiyang (CN), Taizhou First People's Hospital (CN), Wuhan Sixth Hospital (CN), Affiliated Hangzhou First People's Hospital, Westlake University, School of Medicine (CN), Hangzhou Red Cross Hospital (CN), Central Hospital of Zibo (CN), Ningbo University Affiliated Hospital (CN), Dongyang People's Hospital (CN), Shaoxing People's Hospital (CN), First Hospital of Lanzhou University (CN), Changshu No. 2 People's Hospital, Southern Medical University (CN), Lanzhou University (CN)
Good health and well-being
Openalex Percentile: Top 12%
Diabetes Treatment and Management
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.